Nanocopoeia Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NANOCOPOEIA, and when can generic versions of NANOCOPOEIA drugs launch?
NANOCOPOEIA has one approved drug.
There are three US patents protecting NANOCOPOEIA drugs.
There are six patent family members on NANOCOPOEIA drugs in six countries and eleven supplementary protection certificates in ten countries.
Summary for Nanocopoeia
| International Patents: | 6 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Nanocopoeia
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-002 | Dec 5, 2023 | RX | Yes | No | 11,298,356 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-003 | Dec 5, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-001 | Dec 5, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-001 | Dec 5, 2023 | RX | Yes | No | 11,324,745 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nanocopoeia Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2021210974 | ⤷ Subscribe |
| European Patent Office | 4093379 | ⤷ Subscribe |
| Japan | 2023513444 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2021150981 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nanocopoeia Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1169038 | 132013902119320 | Italy | ⤷ Subscribe | PRODUCT NAME: DASATINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(SPRYCEL); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/06/363/001 A EU/I/06/363/015, 20061120 |
| 1169038 | 2013/003 | Ireland | ⤷ Subscribe | PRODUCT NAME: DASATINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120 |
| 1169038 | 13C0003 | France | ⤷ Subscribe | PRODUCT NAME: DASATINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/06/363/001 20061122 |
| 1169038 | 6/2013 | Austria | ⤷ Subscribe | PRODUCT NAME: DASATINIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
